implant growth robot bit
set high expect maintain neutral
maintain neutral rate follow result
miss expect revenue estimate
consensu estim adj ep beat howev
come vs btig/consensu estimate spinal implant
growth y/i net emerg made much robot
unit miss robot unit sale could caus concern
investor bar suffici high robot unit sale result
print management note octob alreadi
respect unit sale certain necessarili larg number
given one sold/plac unit ou robot
dynam asid spinal hardwar result continu strengthen q/q
npi addit rep come non-compet
hardwar growth continu ultim maintain neutral
feel current valuat leav limit room error upsid
right cadenc excelsiu sale beyond
key question mind come management
commentari note season competit debut nass
factor led sale worri new entrant
space nuvas buy pt puls redoubl
effort neutral analyst lavin
factor play next year could slow sale cycl
addit begin start lap excelsiu comp
strong gate
margin continu come expect management note declin
gm adj ebitda margin sequenti driven continu
price pressur biolog mix invest sets/peopl
trauma roll-out believ room give margin
investor becom concern said pick spend
trauma roll-out outer year may carri cost
time produc meaning revenu
valuat rate neutral risk discuss
btig estim compani document million except per share amount
pleas read import disclosur analyst certif appear appendix
globu report result overal revenu came
come btig estim beat consensu expect
call respect segment report
spine product sale versu expect call
emerg technolog robot trauma came
miss estim estim excelsiusgp
system sold quarter estim miss emerg
larg driven lower expect excelsiusgp shipment larg due
season late nass confer gross margin
ahead estim benefit deprec chang set deploy
sg percentag revenu came versu
expect call revenu
expect told ep quarter versu estim
call
made follow chang model
revenu side adjust expect robot unit quarter
ad unit ultim expect chang much
look ahead lower expect robot
sale move base cadenc higher
capit sale cycl also rais spinal implant product expect
actualsbtig estimate variancetot net bpssg spend bpsr spend bpsebit bpstax bpssourc btig research estim compani filingsvari
slightli account addit product introduct new
rep addit subsequ pull-through hardwar grow
 lower gm expect tweak opex slightli
land in-lin management guidanc look ahead ep
estim move much expect spend
continu move higher management reinvest tax save believ sg
expens go extent model continu
minim leverag may see anyth
believ expens could go higher continu hire rep
similar cadenc
rate neutral share trade ntm ep
estim ntm ev/ebitda rel comp group ntm
ep ntm ev/ebitda feel fair leav limit room
upsid share btig publish price target neutral rate stock
risk rate includ competit sale forc retent
increase/slowdown spine procedur better expens manag
anticip benefit robot spinal hardwar sale hospit capital-expenditure
concentr vote control
btig research estim compani filingsnewold chang
incom etot y/i sale time oper incom incom tax expens net incom share gaap net incom oper expens btig research estim compani report
btig cover compani mention report
appendix analyst certif import disclosur
